Francque Sven M, Marchesini Giulio, Kautz Achim, Walmsley Martine, Dorner Rebecca, Lazarus Jeffrey V, Zelber-Sagi Shira, Hallsworth Kate, Busetto Luca, Frühbeck Gema, Dicker Dror, Woodward Euan, Korenjak Marko, Willemse José, Koek Gerardus H, Vinker Shlomo, Ungan Mehmet, Mendive Juan M, Lionis Christos
Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium.
Laboratory of Experimental Medicine and Paediatrics (LEMP), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
JHEP Rep. 2021 Sep 17;3(5):100322. doi: 10.1016/j.jhepr.2021.100322. eCollection 2021 Oct.
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.
本患者指南适用于所有有非酒精性脂肪性肝病（NAFLD）风险或患有该疾病的患者。NAFLD是全球最常见的慢性肝病，疾病负担很高。然而，人们对此病的知晓程度很低。此外，该疾病的许多方面仍有待阐明，这对向患者提供（或未提供）的信息产生了重要影响。其管理需要患者与其众多医疗服务提供者之间密切互动。患者充分了解NAFLD很重要，以便他们能够在疾病管理中发挥积极作用。本指南总结了与NAFLD及其管理相关的当前知识。它由患者、患者代表、临床医生和科学家共同制定，基于当前的科学建议，旨在支持患者做出明智的决策。
